Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
The monthly injectable regimen comprising the INSTI* cabotegravir and the NNRTI** rilpivirine long-acting (CAB+RPV LA) maintained virological suppression (ie, plasma HIV-1 RNA <50 copies/mL) in almost all participants of the phase III ATLAS*** trial who entered the extension phase, according to the 96-week analysis presented at HIV Glasgow 2020.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.
Switching to a single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains virologic suppression over 72 weeks in older people living with HIV (PLWH), according to a study presented at the HIV Glasgow 2020 Congress.
An oral lead-in (OLI) regimen consisting of cabotegravir + rilpivirine (CAB+RPV) did not seem to have an effect on HIV patients who switched from a daily oral dolutegravir/abacavir/lamivudine (ABC/DTG/3TC) regimen to a monthly injectable CAB+RPV long-acting (LA) therapeutic regimen, given the similar efficacy, safety, and tolerability profiles observed with or without OLI, according to the 124-week results of the phase III FLAIR* trial presented at HIV Glasgow 2020.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.